nach oben

Current Pulmonology Reports

Erschienen in:

01.12.2015 | Bronchiectasis (G Tino, Section Editor)

Diagnostic approach to bronchiectasis

verfasst von: Daniel J. Dorgan, Gregory Tino, Anne O’Donnell

Erschienen in: Current Pulmonology Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Bronchiectasis has been noted at increasing rates in recent years. It is associated with significant morbidity and mortality, although there is a wide range in the severity of bronchiectasis in different patients. There are many different potential causes of bronchiectasis. The aim of this review is to provide a structured approach to the clinical assessment of patients with known or suspected bronchiectasis, including evaluation of severity, airway microbiology, and potential causes of bronchiectasis. The discussion includes a rationale for each component of the diagnostic workup, including how certain diagnostic features can impact treatment, but this is not a comprehensive review of bronchiectasis treatment.

Barker AF. Bronchiectasis. N Engl J Med. 2002;346:1383–93.CrossRefPubMed

Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432–9.PubMedCentralCrossRefPubMed

Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest. 2010;138(4):944–9.PubMedCentralCrossRefPubMed

Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205–9.CrossRef

McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.CrossRefPubMed

6.••

Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:i1–i58. This is the most comprehensive assessment to date of the evidence base for management of bronchiectasis, including grading of the evidence for all recommendations.CrossRefPubMed

Onen ZP, Gulbay BE, Sen E, Yildiz OA, Saryal S, Acican T, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007;101:1390–7.CrossRefPubMed

Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34:843–9.CrossRefPubMed

9.•

Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index: an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85. This study provides the most rigorous criteria for assessing the clinical severity of bronchiectasis. It is useful in the assessment of prognosis and when deciding treatment priorities in bronchiectasis.PubMedCentralCrossRefPubMed

10.

Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1997;155:2041–6.CrossRefPubMed

11.

Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.CrossRefPubMed

12.

Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA. 2013;309(12):1251–9.CrossRefPubMed

13.

Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA. 2013;309(12):1260–7.CrossRefPubMed

14.

Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE). Lancet. 2012;380:660–67.CrossRefPubMed

15.••

Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007;101:1163–70. This study is the largest studies assessing the underlying etiologies of bronchiectasis.CrossRefPubMed

16.••

Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4):1277–84. This study is the largest studies assessing the underlying etiologies of bronchiectasis. CrossRefPubMed

17.

McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012;142:159–67.CrossRefPubMed

18.

Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology. 1993;187:777–82.CrossRefPubMed

19.

Szymanski EP, Leung JM, Fowler CJ, et al. Pulmonary nontuberculous mycobacterial infection: a multisystem multigenic disease. Am J Respir Crit Care Med. 2015. doi:10.1164/rccm.201502-0387OC.PubMed

20.

Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013;187:197–205.CrossRefPubMed

21.

Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013;34:110–23.CrossRefPubMed

22.

Cole PJ. Inflammation: a two-edged sword—the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.PubMed

23.

Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann Intern Med. 2001;135:165–74.CrossRefPubMed

24.

Pifferi M, Di Cicco M, Bush A, et al. Uncommon pulmonary presentation of IgG 4-related disease in a 15-year-old boy. Chest. 2013;144(2):669–71.CrossRefPubMed

25.

CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(No. RR-14).

26.

Chalmers JD, McHugh BJ, Doherty C, et al. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respir Med. 2013;1:224–32.CrossRefPubMed

27.

Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001.CrossRefPubMed

28.

Bienvenu T, Sermet-Gaudelus I, Burgel P-R, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2010;181:1078–84.CrossRefPubMed

29.

Hubert D, Fajac I, Bienvenu T, et al. Diagnosis of cystic fibrosis in adults with diffuse bronchiectasis. J Cyst Fibros. 2004;3:15–22.CrossRefPubMed

30.

Stewart B, Zabner J, Shuber AP, et al. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med. 1995;151:899–903.CrossRefPubMed

31.

Ramsey BW, Davies J, McElvaney MG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New Engl J Med. 2011;365:1663–72.PubMedCentralCrossRefPubMed

32.

Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New Engl J Med. 2015;373:220–31.CrossRefPubMed

33.

Katsuhara K, Kawamoto S, Wakabayashi T, Belsky JL. Situs inversus totalis and Kartagener’s syndrome in a Japanese population. Chest. 1972;61(1):56–61.CrossRefPubMed

34.

Torgersen J. Situs inversus, asymmetry, and twinning. Am J Hum Genet. 1950;2(4):361–70.PubMedCentralPubMed

35.

Shapiro AJ, Davis SD, Ferkol T, et al. Laterality defects other than situs inversus totalis in primary ciliary dyskinesia. Chest. 2014;146(5):1176–86.PubMedCentralCrossRefPubMed

36.

Leigh MW, Hazucha MJ, Chawla KK, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc. 2013;10(6):574–81.PubMedCentralCrossRefPubMed

37.

Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med. 2013;188:913–22.PubMedCentralCrossRefPubMed

38.

Greenberger PA, Miller TP, Roberts M, et al. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy. 1993;70:333–8.PubMed

39.

Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86:405–14.CrossRefPubMed

40.

Angus RM, Davies ML, Cowan MD, et al. Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus fumigatus. Thorax. 1994;49:586–9.PubMedCentralCrossRefPubMed

41.

Krustins E, Kravale Z, Buls A. Mounier-Kuhn syndrome or tracheobronchomegaly. Respir Med. 2013;107:1822–8.CrossRefPubMed

42.

Willams H, Campbell P. Generalized bronchiectasis associated with deficiency of cartilage in the bronchial tree. Arch Dis Child. 1960;35:182–91.CrossRef

43.

Demourelle MK, Weisman MH, Simonian PL, et al. Brief report: airways anomalies and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64:1756–61.CrossRef

44.

Soto-Cardenas MJ, Perez-De-Lis M, Bove A, et al. Bronchiectasis in primary Sjogren’s syndrome: prevalence and clinical significance. Clin Exp Rheumatol. 2010;28:647–53.PubMed

45.

McMahon MJ, Swinson DR, Shettar S, et al. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis. 1993;52:776–9.PubMedCentralCrossRefPubMed

46.

Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J. 2000;15:5–10.CrossRefPubMed

47.

Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med. 2003;168:127–1292.CrossRef

48.

Martinez-Garcia M-A, de la Rosa CD, Soler-Cataluna J-J, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823–31.CrossRefPubMed

49.

Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.PubMedCentralPubMed

50.

Rasmussen JE, Sheridan JT, Polk W, et al. Cigarette smoke-induced Ca²⁺ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. J Biol Chem. 2014;289:7671–81.PubMedCentralCrossRefPubMed

Titel: Diagnostic approach to bronchiectasis
verfasst von: Daniel J. Dorgan
Gregory Tino
Anne O’Donnell
Publikationsdatum: 01.12.2015
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 4/2015
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-015-0127-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Computed tomography of smoking-related lung disease: review and update

Waterpipe tobacco-smoking: a new smoking epidemic among the young?

Inhaled antibiotics for bronchiectasis: are we there yet?